Background: Effective prognostic markers are needed for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). This study evaluated the clinical associations of serum vascular endothelial growth factor-A (sVEGF-A) and sVEGF-A₁₆₅b (an anti-angiogenic isoform of VEGF-A) levels with time to remission of AAV in a nationwide Japanese prospective follow-up cohort.

Methods: We collected samples from patients with AAV who were enrolled in the nationwide Japanese cohort study (RemIT-JAV-RPGN). We measured sVEGF-A and sVEGF-A₁₆₅b levels using enzyme-linked immunosorbent assays in 57 serum samples collected 6 months before and after initiation of AAV treatment. Patients were classified based on AAV disease subtypes: microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA).

Results: Results revealed significant reductions in sVEGF-A and sVEGF-A₁₆₅b levels in patients with MPA and EGPA, respectively. However, despite the comparable levels of sVEGF-A and sVEGF-A₁₆₅b during the 6 months of treatment in GPA patients, correlation analysis revealed that the differences in log₂-transformed levels of sVEGF-A and sVEGF-A₁₆₅b were inversely correlated with time to remission in GPA patients.

Conclusion: These results suggest that sVEGF-A and sVEGF-A₁₆₅b can serve as potential markers of time to remission in patients with GPA.

背景：抗中性粒细胞胞浆抗体（ANCA）相关血管炎（AAV）需要有效的预后指标。这项研究评估了全国性日本前瞻性随访中血清血管内皮生长因子A（sVEGF-A）和sVEGF-A ₁₆₅ b（VEGF-A的抗血管生成同种型）水平与AAV缓解时间之间的临床联系。队列。

方法：我们收集了参与日本全国队列研究（RemIT-JAV-RPGN）的AAV患者的样本。我们测量血清VEGF-A和血清VEGF-A ₁₆₅ B水平6个月之前和AAV开始治疗后，收集57个血清样品使用酶联免疫吸附测定法。根据AAV疾病亚型对患者进行分类：镜下性多血管炎（MPA），肉芽肿合并多血管炎（GPA）和嗜酸性肉芽肿合并多血管炎（EGPA）。

结果：结果显示在血清VEGF-A和血清VEGF-A显著减少₁₆₅患者分别为MPA和EGPA，B水平。然而，尽管血清VEGF-A和血清VEGF-A的水平相当₁₆₅在6个月的GPA患者治疗B，相关性分析显示，在日志中的差异_2级血清VEGF-A和血清VEGF-A的水平-转化₁₆₅ b未能成反比与GPA患者的缓解时间相关。

结论：这些结果表明，血清VEGF-A和血清VEGF-A ₁₆₅ b的作为患者的GPA的时间潜在标记来缓解。